Addition requirement for certain pharmaceutical marketing expenses
SF5290 would change Minnesota’s tax law to require taxpayers to add back, for state income and corporate franchise tax purposes, amounts deducted under federal law for direct-to-consumer pharmaceutical marketing expenses. The bill defines that term broadly to include advertising and promotional activities aimed at consumers in the United States, such as television, radio, print, digital, and social media ads, as well as patient outreach and disease-awareness campaigns funded by a pharmaceutical manufacturer and tied to a specific product.
The bill applies to both individual income tax and corporate franchise tax calculations by amending Minnesota Statutes sections 290.0131 and 290.0133. It would take effect for taxable years beginning after December 31, 2026, meaning the change would affect future tax filings rather than current-year returns. In practical terms, the bill would increase Minnesota taxable income for affected taxpayers by disallowing the state tax benefit of these federal deductions.
SF5290 would add a new Minnesota tax adjustment requiring an addition to taxable income for direct-to-consumer pharmaceutical marketing expenses deducted under section 162 of the Internal Revenue Code. This would affect both individuals and corporations subject to Minnesota income or franchise tax, and it would narrow the extent to which pharmaceutical marketing costs reduce state taxable income. The bill does not create a new tax rate or credit; instead, it changes the tax base by decoupling Minnesota from the federal deduction for this category of expenses.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or formal support/opposition in the available record. Based on the bill’s subject matter and structure, the measure appears targeted and policy-specific rather than broadly controversial in the text itself. The available context suggests a straightforward tax policy proposal with no documented legislative sentiment yet.
The main point of contention likely concerns whether Minnesota should disallow a federal deduction for pharmaceutical advertising and promotional spending. Supporters would likely view the bill as limiting tax preferences for drug marketing and potentially discouraging aggressive direct-to-consumer promotion, while opponents may argue it singles out one industry, increases tax liability, and could burden legitimate marketing and patient-awareness efforts. Because there are no transcripts or votes, no specific legislators, agencies, or stakeholder groups are identified in the record as having expressed these views.